A Simple three-step method for design and affinity testing of new antisense peptides: an example of erythropoietin by Štambuk, Nikola et al.
Int. J. Mol. Sci. 2014, 15, 9209-9223; doi:10.3390/ijms15069209 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
A Simple Three-Step Method for Design and Affinity Testing of 
New Antisense Peptides: An Example of Erythropoietin 
Nikola Štambuk 1,†,*, Zoran Manojlović 2, Petra Turčić 3, Roko Martinić 4, Paško Konjevoda 1,†, 
Tin Weitner 5, Piotr Wardega 6 and Mario Gabričević 5 
1 Center for Nuclear Magnetic Resonance, Ruđer Bošković Institute, Bijenička cesta 54,  
10002 Zagreb, Croatia; E-Mail: pkonjev@irb.hr 
2 Croatian Institute for Toxicology and Antidoping, Borongajska 83 g,  
10000 Zagreb, Croatia; E-Mail: zoran.manojlovic@antidoping-hzta.hr 
3 Department of Pharmacology, Faculty of Pharmacy and Biochemistry, University of Zagreb, 
Domagojeva 2, 10000 Zagreb, Croatia; E-Mail: pturcic@pharma.hr 
4 Department for Clinical Pathophysiology, Clinical Hospital Centre Split, Šoltanska 1,  
21000 Split, Croatia; E-Mail: roko.romast@gmail.com 
5 Department of General and Inorganic Chemistry, Faculty of Pharmacy and Biochemistry, 
University of Zagreb, Ante Kovačića 1, 10000 Zagreb, Croatia;  
E-Mails: tweitner@pharma.hr (T.W.); mariog@pharma.hr (M.G.) 
6 NanoTemper Technologies GmbH, Flößergasse 4, 81369 Munich, Germany;  
E-Mail: piotr.wardega@nanotemper.de 
† These authors contributed equally to this work. 
* Author to whom correspondence should be addressed; E-Mail: stambuk@irb.hr;  
Tel./Fax: +385-1-468-0193. 
Received: 30 March 2014; in revised form: 9 May 2014 / Accepted: 12 May 2014 /  
Published: 26 May 2014 
 
Abstract: Antisense peptide technology is a valuable tool for deriving new biologically 
active molecules and performing peptide–receptor modulation. It is based on the fact that 
peptides specified by the complementary (antisense) nucleotide sequences often bind to 
each other with a higher specificity and efficacy. We tested the validity of this concept on 
the example of human erythropoietin, a well-characterized and pharmacologically relevant 
hematopoietic growth factor. The purpose of the work was to present and test simple and 
efficient three-step procedure for the design of an antisense peptide targeting receptor-binding 
site of human erythropoietin. Firstly, we selected the carboxyl-terminal receptor binding 
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region of the molecule (epitope) as a template for the antisense peptide modeling; 
Secondly, we designed an antisense peptide using mRNA transcription of the epitope 
sequence in the 3'→5' direction and computational screening of potential paratope 
structures with BLAST; Thirdly, we evaluated sense–antisense (epitope–paratope) peptide 
binding and affinity by means of fluorescence spectroscopy and microscale thermophoresis. 
Both methods showed similar Kd values of 850 and 816 µM, respectively. The advantages 
of the methods were: fast screening with a small quantity of the sample needed, and 
measurements done within the range of physicochemical parameters resembling physiological 
conditions. Antisense peptides targeting specific erythropoietin region(s) could be used  
for the development of new immunochemical methods. Selected antisense peptides with 
optimal affinity are potential lead compounds for the development of novel diagnostic 
substances, biopharmaceuticals and vaccines. 
Keywords: erythropoietin; antisense; peptide; binding; fluorescence; spectroscopy; 
thermophoresis; modeling 
 
1. Introduction 
In the last two decades antisense peptides became a valuable tool for deriving new biologically 
active molecules and performing peptide–receptor modulation [1–7]. They have been used in 
biomedicine for efficient modeling of more than 40 peptide–receptor systems [1–7]. 
This study presents a simple and efficient three-step procedure for the antisense peptide design and 
the verification of its binding. The first step is the selection of molecular target, i.e., the selection of  
the targeted epitope, which serves as a starting point for the design of an antisense peptide ligand 
(paratope). The second step is the rational design of the antisense peptide paratope directed against the 
selected epitope. Finally, the third step is the evaluation of sense–antisense peptide (epitope–paratope) 
binding by means of fluorescence spectroscopy and microscale thermophoresis, or other appropriate 
physicochemical, immunologic or chromatographic technique. 
Erythropoietin (EPO) is the primary humoral regulator of red blood cells production, i.e., erythropoiesis. 
It is a large glycoprotein with 193 amino acid residues (signal peptide 1–27, chain 28–193),  
and molecular weight of approximately 35,000 (Figure 1) [8–11]. In medicine, EPO is used for 
therapeutic and diagnostic purposes [8–10]. The main therapeutic use is the treatment of anemia 
resulting from chronic kidney disease, while the measurement of serum levels of EPO is important in 
differentiating primary polycythemia from secondary polycythemia [8,9]. EPO derivatives also have a 
history of use as doping agents, especially in endurance sports, because they enhance delivery of 
oxygen to the tissues [10]. 
Due to its pharmacologic relevance erythropoietin molecule is well characterized and suitable for 
the investigation of potential binding sites, which may be of importance for diagnostic and therapeutic 
procedures involving EPO and its derivatives [8–10]. Consequently, we chose EPO as a starting point 
for the design of specific ligand based on antisense peptide technology. 
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Figure 1. (A) Primary and secondary structure of the erythropoietin molecule. G, 310-helix 
(light green); H, α-helix (light green); E, β-strand (light blue); –, coil/other. P1–P5 are 
epitope regions of the molecule (light brown) [11]; (B) Tertiary structure of the 
erythropoietin with its bioactive regions P1–P5 (light brown). 
(A) 
(B) 
2. Results and Discussion 
2.1. Selection of the Molecular Target (Epitope): Step 1 
The first step in antisense peptide design is the selection of the molecular target, i.e., appropriate 
epitope. The principal immunogenic regions/epitopes in vaccine design and related immunochemical 
procedures are interaction sites characterized by high values of hydrophilicity, surface probability  
and antigenic index [12–14]. An alternative approach to the detection of protein interaction sites is  
the Resonant Recognition Method (RRM), based on the Fourier signal analysis of the amino acid  
electron–ion interaction pseudo-potential (EIIP) [15,16]. 
The comparison of these two different methods for the prediction of antibody–protein interaction 
sites is given in Table 1 [13,15]. Classic Hopp and Woods hydrophilicity scale measures averaged 
sums of solvent parameter values in kcal/mol within the fixed length of the window (e.g., 6 aa) to 
extract the information on the most likely antigenic parts of the molecule [13,14]. Resonant Recognition 
Method is a physical and mathematical procedure that interprets protein sequence linear information of 
the electron–ion interaction pseudo-potential in Rydberg’s unit of energy (Ry), using signal analysis in 
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order to extract regions relevant for intermolecular interactions [15]. The correlation between Hopp 
and Woods and EIIP values of the individual amino acids in Table 1 is negligible (r = 0.162, p > 0.05), 
and similar is valid for the EPO sequence comparison in Figure 1 (r = 0.323, p < 0.05), a fact 
suggesting different information qualities of both methods [17]. When both methods are applied to 
EPO molecule the same peaks, i.e., five hot spots P1–P5, are extracted (Figure 2). This points to high 
information content of the selected sites. 
Table 1. Values of amino acid hydrophilicity and electron–ion interaction pseudo-potential 
(EIIP) [13,15]. 
Amino Acid Abbreviation Hopp and Woods Hydrophilicity EIIP (Ry)
Arginine R 3.0 0.0959 
Lysine K 3.0 0.0371 
Aspartic acid D 3.0 0.1263 
Glutamic acid E 3.0 0.0058 
Serine S 0.3 0.0829 
Asparagine N 0.2 0.0036 
Glutamine Q 0.2 0.0761 
Proline P 0.0 0.0198 
Glycine G 0.0 0.0050 
Threonine T −0.4 0.0941 
Histidine H −0.5 0.0242 
Alanine A −0.5 0.0373 
Cysteine C −1.0 0.0829 
Methionine M −1.3 0.0823 
Valine V −1.5 0.0057 
Leucine L −1.8 0.0000 
Isoleucine I −1.8 0.0000 
Tyrosine Y −2.3 0.0516 
Phenylalanine F −2.5 0.0946 
Tryptophan W −3.4 0.0548 
Specific antibody binding has been experimentally verified by Fibi et al. for the regions P2, P4 and 
P5, respectively (Figure 1) [11]. Out of those regions carboxyl-terminal domain P2 was found to be 
involved in the biologic function of recombinant human EPO and its receptor binding site. This was 
verified in vitro using cell proliferation assay based on specific inhibition of the EPO activity with P2 
induced antisera [11]. Considering the consistence of the models with experimental data (Figure 2),  
as well as its functional importance, we selected P2 domain as a target epitope for the next procedure 
steps, i.e., the antisense peptide design (Step 2) and the verification of its binding affinity (Step 3). 
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Figure 2. Single spectrum (Fourier) analysis of the erythropoietin after assigning electron–ion 
interaction pseudo-potential (EIIP) to each amino acid. Frequency = number of cycles per 
observation; Periodogram Value = (sine coefficientk2 + cosine coefficientk2)  N/2; N = number 
of observations in the series. Five dominant frequency peaks identified by the periodogram 
correspond to the immunogenic parts P1–P5 of the erythropoietin molecule. 
 
2.2. Modeling of an Ansisense Peptide (Paratope): Step 2 
Antisense peptide design is closely related to the genetic code structure [1–6]. Sixty-four codons of 
the genetic code consist of three nucleotide bases. Sixty-one codons are for 20 amino acids and three 
are stop signals [1]. The antisense sequences are obtained from the mRNA by transcribing uracil (U) 
into its complement adenine (A) and cytosine (C) into its complement guanine (G), or vice versa  
(Figure 3) [1]. During the last two decades growing experimental evidence supported the thesis that 
sense and antisense mRNAs define peptides that interact with increased probability [1–6]. This biologic 
phenomenon is closely related to the Proteomic Code, a set of rules by which the information 
contained in DNA/RNA sequences is transferred to the physicochemical characteristics of the  
amino acids, protein structure and specific protein–protein interactions [1,2,18]. The concept of 
antisense peptide based modeling of ligand–receptor interactions has been successfully applied to  
many receptor systems, and it became a valuable procedure for the design of new bioactive peptides 
and antibodies [1–6]. 
Biro, Mekler and Idlis first discussed genetic coding of possibly interacting, specific complementary 
(antisense) amino acids [2,18]. Root-Bernstein, Blalock, Siemion and others investigated the 
applications of complementary (antisense) peptides, and critically examined the relevance of such a 
molecular recognition for the modeling of protein/peptide interactions in biomedicine [1–7,18–24]. 
Two main characteristics of the antisense peptide modeling based on the standard genetic code are:  
(1) tendency for opposite polarity patterns of an antisense peptide when compared to the sense peptide 
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structure; (2) different number of antisense peptides depending on the direction of the mRNA 
transcription (from left to right and vice versa; 3'→5'/5'→3') [1,4,6,24]. 
Frequently observed molecular interaction of sense and antisense peptide pairs is related to the 
genetic code property that codons for hydrophobic amino acids are in most cases complemented with 
the hydrophilic ones, while the neutral ones are complemented mutually [1–4,6,20]. This fact is 
illustrated in Figure 3, and results from the triplet codon based structure-function relationship. The second 
(central) nucleotide base of the codon triplet specifies the majority of nonpolar and polar amino acids [3]. 
Consequently, most of the codons containing central uracil and adenine code for the amino acids of 
opposite polarity, and the polarity pattern of antisense peptides is reversed (Figure 3). 
Figure 3. Genetic code table defines 64 nucleotide base triplets of the mRNA, that code for 
20 amino acids and 3 stop codons. (A) Second nucleotide base of the codon triplet codes the 
majority of nonpolar (blue) and polar (red) amino acids; (B) Antisense peptides based on 
mRNA transcription in the 3'→5' direction have less antisense amino acids then those 
transcribed in the 5'→3' direction. u = U, uracil; a = A, adenine; c = C, cytosine; g = G, guanine. 
 
The transcription of the sense peptide into the antisense one may be done in the 3'→5' and/or 5'→3' 
direction. However, from the standpoint of the efficient modeling it is more convenient to use the 
3'→5' direction as a template for an antisense peptide design, since, as presented in Figure 3 and  
Table 2, it results in a significantly fewer peptide structures [4,6,24]. When triplet codons encoding 
sense amino acids are transcribed in the 3'→5' direction there are 27 possible antisense pairs for  
20 amino acids, and when they are transcribed in the 5'→3' direction there are significantly more 
possibilities, i.e., 52 antisense for 20 sense amino acids (Figure 3, Table 2). This results from the fact 
that the transcription of antisense mRNA in 5'→3' direction specifies triplet codons of the genetic code 
table backwards (3rd2nd1st base instead of 1st2nd3rd base, Figure 3). 
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Table 2. Significantly more antisense amino acids are obtained by the mRNA codon 
transcription in the 5'→3' direction then in the 3'→5' direction. 
Amino Acid Antisense 3'→5' Antisense 5'→3' 
F K K, E (η) 
L D, E, N (α) E, Q, K (θ) 
I Y N, D, Y (ι) 
M Y H 
V H, Q (β) H, D, N, Y (κ) 
S S, R (γ) G, R, T, A (λ) 
P G G, W, R (μ) 
T W, C (δ) G, S, C, R (ν) 
A R R, G, S, C (ξ) 
Y M, I (ε) I, V (ο) 
H V V, M (π) 
Q V L 
N L I, V (ρ) 
K F  F, L (ς) 
D L I, V (σ) 
E L L, F (τ) 
C T T, A (υ) 
W T P 
R A, S (ζ) A, S, P, T (φ) 
G P P, S, T, A (χ) 
Antisense peptide technology gave promising results in neuroendocrine and immune research, 
especially with the respect to antibody and paratope design [1–6]. Therefore, we applied this theoretical 
concept to design an antisense peptide targeting receptor-binding site of the human erythropoietin. 
Carboxyl-terminal domain peptide LKLYTGEACRTGDR, i.e., EPO-P2 epitope (152–166 aa),  
was used as a template for the antisense peptide design. 
The algorithm of antisense mRNA transcription in the 3'→5' direction was applied to generate all 
possible antisense peptides representing potential paratopes that may bind targeted EPO-P2 region 
(Tables 2 and 3) [6,24]. Potential antibody structures (paratopes) to EPO-P2 epitope were selected using 
Basic Local Alignment Search Tool (BLAST), with blastp option (protein–protein BLAST) [24,25]. 
The results presented in Table 3 show three antisense pentapeptide motifs contained in human 
antibody structures (αFαεδ, PLRTζ and ζδPLζ—where α = (D, E, N); δ = (W, C); ε = (M, I); ζ = (A, S)). 
The final structure of the antisense peptide DFDIWPLRTAWPLS, presented in Table 4, was obtained 
by joining three linear paratope motifs DFDIW, PLRTA and WPLS, selected on the basis of the 
highest score of antibody homologies detected by BLAST search. Following this step, EPO-P2 epitope 
LKLYTGEACRTGDR and its antisense peptide DFDIWPLRTAWPLS were synthesized. The structures 
of both peptides were analyzed with CD spectroscopy (Figure 4). A strong negative peak with 
maximum around 200 nm was typical for random coil structure, and the absence of any peaks at other 
wavelengths indicated no organized structure in both peptides. 
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Table 3. In silico paratope scan of erythropoietin P2 epitope (152–166) using Basic Local 
Alignment Search Tool (BLAST) [24,25]. 
Antisense 
Paratope 
EPO-P2 Epitope 
KLFLYTGEACRTGDR 
Number of 
Paratopes 
BLAST Detected 
Antibodies 
1 FαFαε 18 6 
2 αFαεδ 36 20 
3 FαεδP 12 0 
4 αεδPL 12 0 
5 εδPLR 4 0 
6 δPLRT 2 0 
7 PLRTζ 4 2 
8 LRTζδ 4 0 
9 RTζδP 4 4 
10 TζδPL 4 6 
11 ζδPLζ 8 12 
α = (D, E, N); δ = (W, C); ε = (M, I); ζ = (A, S). 
Table 4. Antisense peptide DFDIWPLRTAWPLS obtained by joining three linear paratope 
motifs, starting from the antisense paratope 2 selected on the basis of highest number of 
antibody homologies detected by BLAST. 
Antisense Paratope 2 Antisense Paratope 7 Antisense Paratope 11 BLAST Detected Antibodies
DFDIW PLRTA WPLS 17 
Figure 4. Circular dichroism spectra of Erythropoietin (EPO)-P2 peptide and its antisense. 
 
2.3. Evaluation of Peptide Binding: Step 3 
The binding of peptides was evaluated by means of two methods—tryptophan fluorescence 
spectroscopy and microscale thermophoresis. Tryptophan fluorescence data were characterized with 
the SPECFIT software [4,26–29]. Singular value decomposition analysis suggested only two spectrally 
active species, one of the antisense peptide DFDIWPLRTAWPLS and the other of its complex with 
EPO-P2 binding partner, since EPO-P2 is not spectrally active in fluorescence mode. The results, 
presented in Figure 5, suggested 1 to 1 complex formation, without any higher order complexes.  
This model is given by Equations (1) and (2), where Kd is the dissociation constant of the complex: 
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ANTISENSE − EPO-P2 ⇄ ANTISENSE + EPO-P2 (1)
Kd = 
[ANTISENSE][EPO-P2]
[ANTISENSE–EPO-P2]
 (2)
Calculated dissociation constant (Kd) was 850 ± 160 µM (mean ± SD). 
Figure 5. A titration of 2.5 μM solution of EPO-P2 antisense peptide DFDIWPLRTAWPLS 
with EPO-P2 epitope LKLYTGEACRTGDR, at 25 °C, pH = 7.4, 10 mM phosphate buffer. 
The concentration of ligand was varied from 1.2 to 75 μM. Inset: Results of fitting the 
titration data of EPO-P2 antisense with its EPO-P2 ligand at 310 nm, according to the 
model proposed in Equations (1) and (2). 
 
Microscale thermophoresis [30–32] was also used to analyze the binding of EPO-P2 antisense 
peptide DFDIWPLRTAWPLS to EPO-P2 epitope LKLYTGEACRTGDR [30–32]. The data, presented 
in Figure 6, show a single binding event in a micromolar concentration range of the titrant. The dissociation 
constant of the complex (Kd = 816 ± 32 µM) was similar to that obtained by means of the tryptophan 
fluorescence spectroscopy, presented in Figure 5. 
Different methods have been used to evaluate sense–antisense peptide interactions, like microtiter 
plate assay method (immunoassay) and high-performance affinity chromatography, and related 
techniques [20,33–35]. Useful spectroscopical methods for this type of analysis are biosensor based 
surface plasmon resonance and resonant mirror analyses, electrospray ionization mass spectrometry, 
and NMR spectroscopy [1,36–40]. Classical biochemical methods such as enzyme linked immunosorbent 
assay (ELISA) and electrophoretic mobility shift assay (EMSA) are not always repeatable or 
generalisable when complementary peptide binding is observed [7,41]. Similar is valid for the 
chromatographic techniques [7]. 
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Figure 6. Microscale thermophoresis method confirmed the results of fluorescence 
spectroscopy titration presented in Figure 5, thus confirmed the binding of antisense 
paratope DFDIWPLRTAWPLS and its complementary epitope LKLYTGEACRTGDR. 
 
Tryptophan fluorescence method and microscale thermophoresis that we used in this study proved 
to be simple, efficient and sensitive. Their advantage is that the measurement is done within the range 
of physicochemical parameters that resemble physiological conditions [4], and the volume and quantity 
of the sample is small, especially for microscale thermophoresis [30–32]. This fact is important in  
the case of screening a large number of compounds. This represents an advance over the common 
nonfuorescent physicochemical methods such as isothermal titration calorimetry (ITC) or surface 
plasmon resonance (SPR) [41,42]. Tryptophan fluorescence titration and microscale thermophoresis 
can be performed in different buffers, body fluids and cell suspensions/lysates [4,30–32,41–45]. 
Therefore, they provide a novel, immobilization-free and label-free physicochemical approach to study 
molecular interactions of small peptides [41,42]. 
Fluorescence as a method depends only on the change in the fluorophore environment and not on 
the size or type of the molecules [45]. Consequently, it is suitable for the detection of protein–protein 
and peptide–peptide interactions, as well as the quantification of these affinities (Kd) [4,45]. 
Microscale thermophoresis also turned out to be a very appropriate method for the evaluation of 
peptide–peptide interactions, due to large change in the relative size/diffusion of the molecules as 
reactants and as a product species [41–43]. 
3. Experimental Section 
3.1. Erythropoietin (EPO) Molecule Structure 
Primary, secondary and tertiary structures of the EPO molecule (PDB file 1BUY) are presented in 
Figure 1 using Unipro UGENE software [46,47]. Five principal epitopes of the EPO (P1–P5) were 
predicted with the computer program of the University of Wisconsin Genetics Computer Group [11,14]. 
UWGCG software package is a classic collection of algorithms for protein structure/function studies 
including the plots of: hydrophilicity according to Hopp and Woods (Table 1), surface probability 
(Emini et al.), flexibility (Karplus and Schulz), antigenic index (Jameson and Wolf) and secondary 
structure (CF, GOR) [12,14]. In this type of analysis basic information obtained from the molecular 
hydrophilicity is supplemented by other parameters [12,14]. 
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3.2. Resonant Recognition Method (RRM) 
Primary amino acid sequence of the EPO molecule was converted into the numerical series using 
Resonant Recognition Method (RRM) [15]. EIIP value was assigned to each amino acid [15].  
The values of EEIP for 20 amino acids and EPO sequence are given in Table 1. The informational 
spectrum (IS) of the protein sequence in Figure 2 was calculated by means of a single-series  
Fourier analysis in order to obtain highest frequency peaks of the periodogram. According to the 
theoretical concept of RRM those highest peaks (also named hot spots) often belong to the bioactive 
part of the molecule (Figure 2) [15]. Peak position = 2  Frequency  sequence length. Software 
STATISTICA for Windows version 8.0 was used for the analysis [48]. 
3.3. Peptides 
EPO peptide of the P2 region aa 152–166 (EPO-P2, Figure 1). Sequence: LKLYTGEACRTGDR 
(MW 1582.65, >97% purity; GenScript, Piscataway, NJ, USA). Antisense peptide of the EPO-P2 
region. Sequence: DFDIWPLRTAWPLS (MW 1716.50, >97% purity; GenScript). 
3.4. Circular Dichroism Spectroscopy 
The circular dichroism spectra were measured with Jasco J-815 CD spectrometer equipped with 
thermostated cell holder in a rectangular 1 cm cuvette (Jasco Inc., Easton, MD, USA). Conditions: 
concentration of peptides = 1 mg/mL, phosphate buffer = 0.1 M, pH = 7.4, temperature = 25 °C. 
Spectra are presented as averages of five scans, and corrected for buffer spectrum. 
3.5. Tryptophan Fluorescence Spectroscopy 
Fluorescence spectra of the binding peptides and their complexes were measured at 25 °C by OLIS 
RSM 1000F spectrofluorimeter (Olis, Inc., Bogart, GA, USA) equipped with thermostatted cell holder.  
The excitation wavelength was 280 nm. Antisense peptide to EPO-P2 and its complex exhibited 
fluorescence, whereas the EPO-P2 ligand did not. Fluorescence units are given as a ratio of signals 
obtained from sample and reference PMTs. Data obtained from the titrations were analyzed with 
SPECFIT software [4,26–29]. 
3.6. Microscale Thermophoresis 
Microscale thermophoresis experiment of the peptide binding was performed with use of the 
Monolith.NT.LabelFree instrument by measuring gradual thermophoretic pattern changes through 
detection of intrinsic tryptophan fluorescence (NanoTemper Technologies GmbH, Munich,  
Germany) [30–32], in context of EPO-P2 titration into reaction mixture. The concentration of EPO-P2 
antisense peptide DFDIWPLRTAWPLS containing tryptophan was kept constant (10 µM), while the 
concentration of its binding partner, i.e., non-fluorescent EPO-P2 peptide was varied between 10  
and 0.305 µM. A serial dilution of the EPO-P2 peptide (titrant) was prepared starting from 10 mM  
in phosphate buffer. After a short incubation (15 min) the samples were loaded into microscale 
thermophoresis NT.LabelFree standard glass capillaries, and the experiment was performed. 
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4. Conclusions 
We present a simple and efficient three step procedure for the antisense peptide design and the 
verification of its binding using the model of human EPO molecule. 
(1) In the first step the receptor binding region of the EPO molecule was selected as a template for 
the antisense peptide modeling.  
(2) The second step was the rational design of the antisense peptide DFDIWPLRTAWPLS 
(paratope) directed to the selected EPO region (epitope). The method combined antisense mRNA 
transcription of the epitope template in the 3'→5' direction, and computational screening of potential 
paratope structures using Basic Local Alignment Search Tool (BLAST). 
(3) The third step was the evaluation of sense–antisense (epitope–paratope) peptide binding by 
means of the fluorescence spectroscopy and microscale thermophoresis. The advantages of the 
methods were: fast screening with a small quantity of the sample needed, and measurements done 
within the range of physicochemical parameters resembling physiological conditions. 
A simple three-step method presented in this study enables fast, inexpensive and reliable selection 
of antisense peptides with high affinity for specific targets. Antisense peptides to specific EPO 
region(s) could be used for the development of new immunochemical methods that avoid binding 
problems caused by glycosylation or sequence modification. 
The current accent in pharmacological research is modulation of protein–protein interactions,  
and the use of complementary peptides provides insight in such systems [49,50]. The method may be 
easily adapted for high-throughput screening, especially in the context of microscale thermophoresis 
equipment developed for this purpose [42]. Selected antisense peptides with optimal affinity could be 
used as a starting point for the development of novel assays, vaccines, biopharmaceuticals and diagnostic 
substances. However, additional investigations of selectivity and pharmacokinetic properties will be 
required for specific purposes. 
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